HIV antiretroviral therapy in Ethiopia. Overcoming implementation challenges by Dare, Degu Jerene
 
Degu Jerene Dare 
i 
HIV antiretroviral therapy in 
Ethiopia 
Overcoming implementation challenges  
Degu Jerene Dare 
 
 Centre for International Health 
University of Bergen, Norway 
2007 
Thesis submitted in partial fulfilment of the requirements for the degree Philosophiae 
Doctor (PhD) at the University of Bergen, Norway 
 
Degu Jerene Dare 
ii 
Acknowledgements 
My heartfelt gratitude goes to Professor Bernt Lindtjørn, my main supervisor, for his 
excellent scientific guidance and tireless efforts to make this work a reality.  My sincere 
appreciation also goes to professor Are Næss, my co-supervisor, for his scientific input 
and encouragement. I also thank the following staff at CIH for their administrative 
support: Solfrid Hornell, Borgny Lavik, Unni Kvernhuvisk, and Nils Gunnar Songstad. I 
thank the Norwegian government for financing my study through the Quota Scholarship 
scheme.  
 
My sincere appreciation also goes to Dr. Amenu Adam, Arba Minch hospital medical 
director, for his administrative support. Many thanks to Tekle Eyasu for his 
encouragement and friendship throughout my field work even at difficult moments of my 
work. Drs Yewubnesh Hailu and Aschalew Endale actively participated in this project. I 
thank Feven Fetene and Tesfalem Babena, the community agents, and Asnakech 
Abayneh, the data clerk-- for their excellent work. The laboratory work was mainly done 
by Samuel, Negusu, Temesgen and Jemal. Staff at the hospital pharmacy and some 
nurses contributed professionally. Tolossa Tomas and Andinet Assefa were very helpful. 
 
I extend my sincere appreciation to the Norwegian Lutheran Mission in Addis Ababa for 
their administrative support and hospitality. My special thanks to Ato Abera Tajebe, 
NLM finance manager, and staff in his office: Solomon, Meaza, Tiblets, Selome, 
Yeshumnesh, and Kifle.  
 
Degu Jerene Dare 
iii 
 
My family has been a source of pride and encouragement throughout my work. My 
unique appreciation goes to my wife Banchi Million for her exceptional strength, prayer 
and support through out my study stay away from home. I now promise to be with you 
and share the joy of being together. Niftalem and Gediwon, our sons, make my life more 
meaningful. Hi boys, I hope when you grow and read this, you will understand why I was 
not at home most of the time. Thanks to your mom, she was taking a good care of you. 
Thank you Buyes.  
 
I am thankful to my parents (Jerene Dare and Yeshi Ouguna) for their encouragement and 
prayer.  My brothers Yonas, Eyuel, and Yonatan were always there to encourage me. 
Thank you Aynu, Mame and Tsahu for the hospitality.  
 
I also thank Christian friends at Arba Minch Kalehiwot Church for the fellowship, prayer 
and encouragement. I thank members of Ethiopian Christian Fellowship in Bergen for the 
good fellowship we had. 
 
Thank you Lord! Yesusa Ne7ew Holla!. 
 
Degu Jerene Dare 
iv 
Original Papers 
This thesis is based on the following papers, which will be referred to in the text by their 
roman numerals. 
I. Jerene D, Lindtjørn B. Disease progression among untreated HIV infected 
patients in south Ethiopia: Implications for patient care. MedGenMed 2005 Aug 
30; 7(3):66. 
II. Jerene D, Næss A, Lindtjørn B. Antiretroviral therapy at a district hospital in 
Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res 
Ther. 2006 Apr 7; 3(1): 10. 
III. Jerene D, Endale A, Hailu Y, Lindtjørn B. Predictors of early death in a cohort of 
Ethiopian patients treated with HAART. BMC Infect Dis. 2006; 6:136 
IV. Jerene D, Endale A, Lindtjørn B. Acceptability of HIV counselling and testing 
among tuberculosis patients in south Ethiopia. Submitted. 
 
Degu Jerene Dare 
v 
List of Abbreviations 
3TC Lamivudine 
ABC Abacabir 
AIDS Acquired Immune Deficiency Syndrome 
ART Antiretroviral Therapy 
ARVs Antiretroviral drug (s) 
BMI Body Mass Index 
CBC Complete Blood Cell Count 
CDC Centre for Disease Control and Prevention 
D4T Stavudine 
DDI Didanosine 
DOTS Directly Observed Treatment, Short Course 
EFV Efavirenz 
FDA Food and Drug Administration 
HAART Highly Active Antiretroviral Therapy 
HIV Human Immunodeficiency Virus 
IPT Isoniazid Preventive Therapy 
IRIS Immune Reconstitution Inflammatory Syndrome 
LPV/r Ritonavir-boosted lopinavir 
NLM Norwegian Lutheran Mission 
NORAD Norwegian Agency for Development Cooperation 
NRTI (s) Nucleoside Reverse Transcriptase Inhibitor (s) 
 
Degu Jerene Dare 
vi 
NtRTI (s) Nucleotide Reverse Transcriptase Inhibitor (s) 
NVP Nevirapine 
PI (s) Protease Inhibitor (s) 
PYO Person-Years of Observation 
SNNPRS Southern Nations, Nationalities’ and Peoples’ Regional State 
SQV/r Ritonavir-Boosted Saquinavir 
TB Tuberculosis 
TLC Total Lymphocyte Count 
VCT Voluntary Counselling and Testing 




Degu Jerene Dare 
vii 
Executive Summary 
Millions of people have died of HIV during the last 25 years. The highest number of 
deaths occurred in poor African countries where antiretroviral therapy was introduced 
only recently. Treating patients in settings with limited resources continues to be a 
challenge. The aim of this thesis was to improve antiretroviral therapy in Ethiopia. The 
main part of the thesis is based on a cohort of HIV infected patients at a district hospital 
in Ethiopia. We established the cohort before antiretroviral therapy was available in the 
country, and continued the follow-up afterwards. Additionally, we assessed the 
acceptability of HIV testing among tuberculosis patients.  
 
In untreated patients, death and tuberculosis incidence rates were high. HAART 
improved survival and decreased tuberculosis to a level similar to that achieved by 
developed countries during early years. However, both death and tuberculosis continued 
to occur at higher rate especially during the early weeks of treatment.  Patients die 
because of advanced clinical disease stage and very low levels of total lymphocyte count 
at presentation. We also found that HIV testing was not accepted by most of the 
tuberculosis patients, highlighting the need for alternative and additional methods of 
testing more patients. 
 
Despite the limitations inherent in observational studies, the findings in this thesis 
provided useful data that can assist in the implementation of antiretroviral therapy in 
Ethiopia. To improve treatment outcomes, we need to treat patients before they progress 
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to advanced stages. This requires improved counselling and testing practices, and making 
treatment available even in settings with limited laboratory setup. Future studies should 
examine the underlying reasons for death and mechanisms should be in place to further 
improve treatment outcomes.  
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Outline of the HIV Epidemic 
The AIDS epidemic is one of the most destructive epidemics in the history of humankind, 
claiming the lives of about 25 million people since it was recognized in 1981. 1 In 2005 
alone, 3 million people died of AIDS, more than half a million of them being children. An 
estimated 40 million were living with HIV by the end of 2005, including 5 million new 
infections in the same year.  Earlier projections had suggested that about 45 million people 
would be infected between 2002 and 2010 unless the world succeeded with concerted 
preventive effort.2 
 
Sub-Saharan Africa is home to 25.8 million people living with HIV, accounting for two-
thirds of the global figure. 1 This is higher than the 2003 estimate by almost 1 million. 3 An 
estimated 2.4 million people died of HIV in 2005, and a further 3.2 million became infected 
with HIV in the same year. 1 
 
According to the Ministry of Health of Ethiopia, about 4.4% of the population of Ethiopia 
live with HIV. 4 The country’s epidemic is concentrated mainly in urban areas, where HIV 
prevalence among pregnant women has averaged at 12-13% since the mid-1990s’. More 
recent evidence, however, shows the epidemic is spreading to rural areas at faster rate than 
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ever before. 4 Given the high proportion of the rural population (about 85%), the current 
estimated rise of the rural prevalence from 1.9% to 2.6% is of great concern. 4   
 
With about 1.5 million people living with HIV in 2004 and at least half a million children 
orphaned by AIDS, there is a huge task of providing adequate treatment, care and support to 
the affected household. 4 5  By June 2005, only about 10% of eligible HIV infected patients 
were receiving antiretroviral therapy in Ethiopia. 6 According to the WHO, about 211000 
people were estimated to be in need of ART by the end of 2004, and the country had 
declared to treat 93, 000 people by the end of 2005. 7 However, only about 34, 000 patients 
received treatment by the end of May 2006. 8 
 
Transmission and risk factors 
HIV transmits through sexual exposure. Heterosexual intercourse accounts for about 70% of 
the overall sexual transmission in the developing countries. 9 In the Western countries, 
however, homosexual contact is the main mode of sexual transmission. 10 The risk of 
heterosexual transmission of HIV is 0.0003-0.0015 per coital act.11  Presence of genital 
ulcers increases the risk of sexual transmission, as does sexual activity that is associated with 
infected blood .11-14 Sexual transmission depends on the viral load as noted in serodiscordant 
African sexual partners, where transmission was rare at viral loads <1500 copies/ml. 15 
 
Blood and blood products account for a major share of nonsexual HIV transmission. 
Transmission can occur through blood transfusion, injection drug use, occupational 
exposure, or accidental needle sticks. The risk from occupational needle sticks to health care 
workers from known HIV-positive source patients was found to be 0.33-0.5%. 16 17  Deep 
injury, injury with a visibly bloody device, or injury with a device that had been previously 
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used in the source patient's vein or artery increase the risk of HIV acquisition. 17 The risk of 
HIV transmission through blood transfusion is a rare problem in the developed world but is 
significantly higher in developing countries. 18 19 
 
Mother-to-child transmission occurs in about 25% of live births to HIV-infected mothers.20 
Transmission occurs either during pregnancy, during delivery or during breast-feeding. 
Roughly one-third of cases of mother-to-child transmission result from breast-feeding, the 
risk increases with duration of breast-feeding, and the chance of breast-milk transmission of 
HIV is 0.00064 per litre of breast-milk ingested. 21 Other body fluids that are known to 
harbour HIV include seminal fluid, pre-ejaculate, vaginal secretions, cerebrospinal fluid, 
saliva, tears, and breast milk of infected individuals. 22-25 No cases of HIV infection have 
been documented to arise from contact with non-bloody saliva or tears. 
 
Natural history and classification of HIV disease 
Initial infection with HIV is non-specific, often without any symptoms or signs.  Some 
infected persons experience a short, flu-like illness about 2-5 weeks after infection. This is 
known as acute viral syndrome of primary HIV infection. Because of the similarity of the 
syndrome with any acute febrile illness, diagnosis is often missed. Careful evaluation of 
prospective data, however,  showed that about 87% of individuals who acquire HIV 
experience some of these symptoms. 26-32 Serologic diagnosis with routine HIV antibody 
tests is often delayed until several weeks or months after infection.32  
 
After the period of acute HIV infection, a relative equilibrium between viral replication and 
the host immune response is reached, and individuals may have little or no clinical 
manifestations of HIV infection. This time between initial infection and the development of 
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AIDS--the chronic HIV infection period-- may be long, averaging 10 years, even in the 
absence of treatment. 33 There was initial speculation that annual progression rates from HIV 
infection to AIDS was shorter in females than in males, and in developing countries than in 
developed countries, but the available data suggest that no major differences exist. 34-41 
 
After variable period of chronic infection, patients eventually progress to AIDS and then to 
death. The US Centre for Disease Prevention and Control (CDC) defines AIDS by either 
diagnosis of AIDS-defining events, or by measurement of CD4 levels <200cells/mcL. The 
median survival time from AIDS to death is about 10 months, though it may vary according 
to the AIDS-defining event. 42 
 
 In Africa, the natural course of HIV disease has not been well studied .37 There is only one 
study from rural Uganda describing the natural history of HIV disease.38 Since effective 
therapy is now available, studying the natural course of untreated HIV disease is unethical.  
 
Currently, there are two systems of classifying HIV disease, the CDC classification and the 
WHO Staging. 43 The CDC classification has existed since 1982, before HIV was identified. 
44 It has been updated several times and the most recent classification includes CD4 
measurement as part of essential criteria.  45 The CDC classification was originally designed 
for surveillance purpose, but its use in clinical practice has increased over time.  
 
The WHO staging system has existed since 1990 and it is mainly based on clinical 
parameters. 46 47 Both presumptive and confirmed clinical diagnosis is allowed in this 
staging. Resource-poor countries use the WHO staging routinely both in surveillance and in 
clinical practice.  
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Management of opportunistic infections 
Because of improved treatment and prophylaxis of opportunistic infections, survival in HIV 
infected patients in the developed world had improved even before HAART was available. 48  
Some studies in developing countries also showed the effectiveness of co-trimoxazole in 
preventing several opportunistic infections. 49-52 Based on the available evidence, the WHO 
has recently issued a guideline for the use of cotrimoxazole in resource-limited settings. 53 
Unlike the CDC recommendation, which needs CD4 measurement, 54 the WHO guideline 
encourages the use of clinical criteria for starting and stopping cotrimoxazole prophylaxis.  
 
However, the shortage of the data and other issues special to the resource-limited settings 
make implementing cotrimoxazole prophylaxis difficult. In settings with no facilities for 
CD4 testing, the time of beginning and discontinuation of cotrimoxazole prophylaxis is 
arbitrary. Even when the CD4 test can be done, there is no consensus on the timing of the 
initiation and discontinuation of cotrimoxazole. Other challenges in developing countries 
include high background resistance patterns, poor adherence, and overlapping toxicities with 
antituberculosis and antiretroviral drugs.  
 
In Ethiopia, no study has evaluated the preventive effect of cotrimoxazole prophylaxis. The 
resistance pattern could be high given the wide availability of the drug on over-the-counter 
basis.  Since decisions on the specific recommendations of cotrimoxazole prophylaxis are 
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Tuberculosis and HIV 
Tuberculosis is the leading cause of sickness and death among HIV infected patients in sub-
Saharan Africa. Unlike other HIV-related infections, tuberculosis occurs at all levels of CD4 
count, is infectious, and its prevention is a major public-health priority. 55 In countries with 
high HIV burden, the current tuberculosis treatment has not been successful. As a result, 
efforts are under way to harmonize the management of the two diseases.56-58 Ethiopia 
follows the directly observed treatment, short course (DOTS) strategy for tuberculosis 
treatment. However, Isoniazid (INH) preventive therapy (IPT) has not been carried out in the 
country. In the recently developed TB/HIV guideline, both co-trimoxazole prophylaxis and 
IPT are recommended. 59 Such effort would entail some change in the current HIV 
counselling and testing strategy. The traditional voluntary counselling and testing (VCT) is 
viewed as a cost-effective strategy that can serve as a gateway to most HIV-related services.  
60-62 However, its acceptability has been low among different client populations. 63-65  
 
Some authors assessed the acceptability of VCT among TB patients 66, while others 
evaluated the acceptability of screening for TB among VCT clients . 67 In the former study in 
Malawi, authors concluded that VCT and adjunctive cotrimoxazole therapy is feasible, safe 
and reduces mortality rates in TB patients under routine programme conditions. 66 The group 
from Haiti reported high prevalence of active pulmonary tuberculosis among VCT clients 
and they stressed the need to integrate  the two programmes. 67 Despite WHO 
recommendations, there is a need for creative application of rigorous scientific approaches to 
identify suitable ways of doing it. 68 
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In Ethiopia, TB/HIV co-infection is high, with about 45% of sputum-smear-positive 
pulmonary TB patients being HIV positive. 69 The HIV epidemic is considered to be a major 
threat to the tuberculosis control efforts in Ethiopia . 70  According to the recently developed 
TB/HIV guideline, HIV counselling and testing will be part of the routine care for 
tuberculosis patients. 71 However, potential barriers to the successful implementation of the 
program such as low acceptability of HIV counselling and testing have not been studied.  
  
1.2 Antiretroviral therapy 
A decade ago, having AIDS was almost equivalent to a death sentence. Since 1996, with the 
introduction of combined antiretroviral treatment,AIDS has become chronic, manageable 
disease.72 Currently, there are about 21 Food and Drug Administration (FDA) approved anti-
retroviral drugs (ARVs) in the world. 73 Three classes of ARVs are now available: 
Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), and protease inhibitors (PIs). Entry and Fusion Inhibitors have also 
emerged as additional class of antiretroviral drugs. 74 
 
When to start treatment 
WHO recommends that in resource-limited settings HIV infected adolescents and adults 
should start antiretroviral therapy when the following conditions are met: 75 
• WHO stage 4 disease (clinical AIDS), regardless of CD4 count 
• WHO stage 3 disease with consideration of CD4 count <350/mm3 in assisting 
decision making 
• WHO stages 1 or 2 disease with CD4 count<200/mm3. 
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In settings where CD4 count is not available, the total lymphocyte count (TLC) can be used, 
and treatment is recommended for: 
• WHO stage 3 or 4 disease (clinical AIDS) irrespective of the TLC 
• WHO stage 2 disease with TLC <=1200/mm3 
 
Although the TLC predicts survival in untreated patients, the exact cut-off point for 
beginning treatment remains controversial. 47 76 77This is a clear indication for a more 
rigorous scientific data in the appropriate setting. 
 
Drug regimens 
The WHO encourages a public health approach to ease the scale-up of ARV use in resource-
limited settings. 75This approach advises that ARV treatment programmes be standardized to 
reach as many patients as possible. Therefore, countries select their own first line regimens 
and a limited number of second-line regimens. Selection of the regimens depends on several 
reasons: potency, side effects, laboratory monitoring requirements, potential for maintenance 
of future treatment choices, expected patient adherence, coexisting conditions, pregnancy or 
the risk of it, availability and cost.75 78 79 
 
WHO recommends a combination of 2 NRTIs+1NNRTI as first-line regimen for resource-
poor countries. The use of five-formulary approach (d4T or ZDV) +3TC+ (NVP or EFV) 
gives four possible combinations and provides options for substitution of toxicity. Each of 
the possible combinations are equally potent . Protease inhibitors (PI) are suggested in case 
resistance to NNRTIs is known to exist. HIV-2 and HIV-1 group O are often resistant to 
NNRTIs-based regimens. 75 
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In treatment failure, the entire first line drugs should be changed to a second line regimen. 
The second-line drugs should include at least three new drugs, one or more of them from a 
new class. This increases the likelihood of treatment success and minimizes the chance of 
cross-resistance. The second-line regimen requires a switch from (d4T or ZDV) +3TC+ 
(NVP or EFV) to (TDF or ABC) +ddI+ (LPV/r or SQV/r). 75  
 
Since publishing the first WHO guideline in April 2002, 80 more evidence has been obtained 
on the effectiveness of HAART in resource-limited settings. However, more work is needed 
to clarify its effectiveness under routine care conditions. As regional variations in viral 
subtypes and co morbid conditions may affect treatment outcomes, we need region-specific 
or country-specific information.  
 
Monitoring Antiretroviral Therapy 
Monitoring antiretroviral therapy starts before starting treatment. Once treatment is started, 
there are four essential aspects of monitoring: therapeutic response, drug toxicity, adherence 
to medication regimens, and monitoring for viral resistance. 81 
 
Monitoring for therapeutic response 
Current North American and European clinical care guidelines incorporate measurements of 
plasma HIV RNA load and CD4 T-lymphocytes for overseeing response to antiretroviral 
therapy. 82 83 Since such techniques are not affordable in resource-limited settings, adapted 
version of these guidelines have been provided. WHO, for example, recommends that ART 
can be started where only HIV antibody test and Haemoglobin (Hgb) or Haematocrit (Hct) 
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can be done. 75 Others have suggested syndromic approach for monitoring response to 
antiretroviral therapy. 84 85  
 
Clinical monitoring alone might result in continued therapy despite emergence of drug 
resistance. Though viral load measurement allows for early detection of viral rebound, it is 
expensive and may compete with scarce resources in resource-limited settings. Identifying a 
balanced monitoring method suitable for the resource-limited settings is thus a priority. 81 
 
Monitoring for drug toxicity 
Almost all antiretroviral drugs have some adverse effects. These toxicities could be specific 
to a single drug, shared by a class of drugs, or could be shared by all antiretroviral drugs. 
Also, some of the drugs have toxicities shared by other drugs commonly used in HIV 
infected patients. 86 In general, drug toxicity can be classified into four categories: 
mitochondrial toxicity, hypersensitivity, lipodystrophy syndrome, and other adverse events 
and special circumstances .87  
 
NRTIs and nucleotide-analogue reverse-transcriptase inhibitors (NtRTIs) cause toxicity by 
inhibiting a mitochondrial enzyme responsible for energy synthesis. 88 The symptoms occur 
in organs rich in mitochondria such as muscles, nerves, liver and  pancreas. The patient may 
thus complain of muscle aches (myopathy), pain in the nerve roots (neuropathy), or 
symptoms suggestive of liver or pancreatic injury. The clinical symptoms are often of 
gradual onset and offset. 
 
Drug hypersensitivity could be up to 100 times more common in HIV-infected patients than 
in the general population. 89Typically, patients present with an erythematous, maculopapular, 
HIV antiretroviral therapy in Ethiopia 
Degu Jerene Dare 
11
pruritic, and confluent rash with or without fever. The rash usually begins after 1-3 weeks’ 
therapy. All NNRTIs, the NRTI abacabir, and the protease inhibitor amprenavir are 
commonly associated with drug hypersensitivity. About half of hypersensitivities associated 
with antiretroviral drugs resolve spontaneously. 87 
 
The main clinical features of the lipodystrophy syndrome associated with antiretroviral drugs 
include peripheral fat loss and central fat accumulation.90 Other side effects include anaemia, 
gastrointestinal symptoms, and teratogenicity. 
 
The best methods for monitoring drug toxicities are still unclear even for developed 
countries. 82 In resource-limited settings, both the size of drug toxicity and its monitoring 
methods are poorly documented. As with monitoring the response to therapy, there are trade-
offs between intensive and less intense watching of toxicity. 81 Patients with moderate or 
even severe elevations in liver enzyme levels may have no detectable symptoms or signs. 
For such patients, relying on clinical evaluation may result in deaths that might be prevented 
by more intensive monitoring strategies. 
 
Monitoring for adherence to medication regimens 
Poor adherence to medication is a common problem everywhere. Adherence to other chronic 
medications is about 50-75%.91 Since treatment outcome (measured virologically) is 
sensitive to slight changes in adherence, about 95% adherence is recommended for 
antiretroviral therapy. 92-94 
 
Getting such high-level of adherence may be problematic. Poor adherence is not uncommon 
even in the industrialized world. 95 Both success and failure stories have been reported form 
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developing countries. 96 Speculations that poor adherence could lead to development of drug 
resistance have been challenged by some reports of high level of adherence in resource-poor 
settings. 97 Also, the relationship between adherence and resistance is bidirectional. 98 High-
level of adherence in the presence of partial viral suppression in fact leads to higher chance 
of resistance. Among patients with complete viral suppression, development of viral 
resistance is less likely with high level of adherence.  
 
Adherence to HAART is affected by the same reasons that are associated with adherence to 
other medications. 99 100  These factors could be related to the patient, the medication or 
health care. Interventions to improve adherence should take all these reasons into account. 
Such interventions could be patient-focused (education, reminders, rewards and 
reinforcement), provider-focused (continuing medical education, cues and instruments, etc.), 
or regimen-focused (decreasing frequency of dosing and pill burden, reduced cost). Often 
combinations of various strategies are used to improve adherence. 100 
 
Monitoring for drug resistance 
Resistance to antiretroviral agents occurred soon after they were introduced. 101 Causes for 
viral resistance include poor drug absorption, drug-drug interactions, variable drug 
metabolism, and poor adherence. The baseline resistance pattern in resource-poor settings is 
unknown, and the best approach to resistance monitoring remains poorly documented. Some 
have suggested sentinel resistance monitoring for centrally designed programmes. 81 
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1.3 Treatment versus prevention 
Prevention is the most important strategy to halt the AIDS pandemic, and one of the final 
tools for prevention is introducing an HIV vaccine. However, the inconsistency of the 
success of prevention programmes and the little hope of having a vaccine in any near future  
provide grounds for looking more seriously at care for AIDS patients in resource-poor 
countries.102 103   
 
Effective ways of interrupting the course of HIV disease progression have existed since 
shortly after the discovery of the virus. 104 However, antiretroviral therapy was limited only 
to the developed countries until recent years. The main barrier was the cost of antiretroviral 
drugs and laboratory expenses. 105-107 Because of political pressure,  access to ART has now 
improved remarkably .6 108 109 
 
However, only a small fraction of patients on the hardest-hit countries are now on ART. By 
June 2005, only one in ten Africans were getting treatment .6 A more recent report shows a 
large increase  (17%) in access to ART in sub-Saharan Africa. 110 Though the 3 by 5 
initiative did not meet its target of treating 3 million people by the end of 2005, it provided 
the foundation for the Universal Access by the year 2010 as pledged by the international 
community. 111 112 
 
Debates about whether to prioritize treatment or prevention seem to be changing. 113 114 The 
current literature supports the synergistic  effect of treatment and prevention .115-117 
Successful treatment makes prevention more acceptable and effective, and effective 
prevention makes treatment more affordable and sustainable. Widespread access to treatment 
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could bring many people into health-care settings, providing new opportunities for health-
care workers to deliver and reinforce HIV prevention messages and interventions. 117  
Improved access to HIV testing provides an entry point to both prevention and treatment 
services. Effective prevention leads to decline in new infections therefore finally will lead to 
a decrease in the number of people who will need treatment. 117 The current debate is not 
whether to prioritize treatment or prevention. The question is how to carry out both 
prevention and treatment in an effective way.  
  
1.4 Rationale for the present study 
There is no single proven model for delivering ART .118 In resource-poor settings, little is 
known about the effect of treatment on patient survival and quality of life. Treatment 
guidelines are from the developed world. 75 78 80 This highlights the urgent need for 
generating regionally suitable data. We started our study when Ethiopia was planning for a 
large-scale ART programme. Successful implementation of such initiatives needs scientific 
evidence generated in the appropriate settings.  
 
In this study, we tried to answer some questions that remain unanswered regarding 
implementation of ART in resource-poor settings. Our study on the natural course of disease 
progression (Paper I) defines pre-ART mortality and tuberculosis incidence rates, and 
provided useful data against which the clinical benefits of ART could be measured. It also 
identified a set of predictor models to guide clinical decision- making  and economic 
analysis. The effectiveness of  HAART could vary from region to region because of the 
difference in background disease burden (such as tuberculosis or intestinal parasites), viral 
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subtypes, and possible genetic differences in drug metabolism. However, such arguments are 
based on little data from the resource-limited settings. We set out to show the effectiveness 
of HAART under routine care conditions in south Ethiopia (Paper II). In further search for 
factors associated with increased mortality in treated patients, we evaluated a set of simple 
clinical and laboratory values as potential predictors of death (Paper III). As tuberculosis 
was an important infection in this setting (Paper I and II), we evaluated ways of integrating 
the management of the two infections using counselling and testing as entry point (Paper 
IV).  
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2 STUDY AIMS 
Overall aim 
The overall aim of this thesis was to improve antiretroviral therapy in Ethiopia.  
 
Specific aims  
1. To describe the pattern and predictors of HIV disease progression among untreated 
HIV infected patients (Paper I). 
2. To assess the effect of antiretroviral therapy on patient mortality and tuberculosis 
incidence rate (Paper II). 
3. To identify risk factors for mortality in patients treated with antiretroviral therapy 
(Paper III).  
4. To identify appropriate ways of incorporating HIV screening as routine care for 
tuberculosis patients (Paper IV). 
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3 METHODS 
3.1 Study area background 
Ethiopia is located in Eastern Africa (See Map). The country has an estimated population of 
75 million, with those aged 15-64 years accounting for 54% of the total population. The 
population growth rate is 2.3%.  Ethiopia is a poor country with 50% of the population being 
below poverty line.   119  
 
Figure 1 Map of Ethiopia showing the study area, Arba Minch, and catchment area of Arba 
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Ethiopia has one of the worst health status in the world, with infectious and communicable 
diseases and nutritional problems accounting for 60-80% of health problems. 120 121  Table 3-
1 summarizes selected demographic and health indicators for Ethiopia. 
Table 1 Selected demographic and health indicators for Ethiopia 
Indicator Rate 
Life expectancy at birth in years (Male, Female) 53.4, 55.4* 
Infant Mortality rate per 1000 77** 
Under five mortality rate per 1000 123** 
Adult HIV prevalence rate (%) 4.4* 
* Source is reference 120 ** Source is reference 121 
 
The Southern Nations, Nationalities, and Peoples’ Regional State (SNNPRS) is the third 
most populous region in Ethiopia with population of about 14 million. There are 13 zones 
(districts) and 52 woredas (sub districts) in the region. Most of the people are subsistence 
farmers, and over 93% of the population lives in rural areas. Infectious diseases account for 
the majority of health problems in the region. The HIV prevalence is estimated at 11.0 and 
3.2% in the urban and rural areas, respectively. 122 
 
Gamo Goffa is one of the 13 districts in the SNNPRS with an estimated population of 1.5 
million. Its capital, Arba Minch, is located 500 km south of Addis Ababa, and 275 Km from 
Awassa, the regional capital. Infectious diseases make up the major share of disease load in 
the district with malaria ranking first. 123  
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Arba Minch Hospital  
 Arba Minch Hospital is a 158-bed general hospital serving a population of about 1.5 
million. The hospital provides general outpatient service, surgical and obstetric emergency 
and regular services, and general medical and paediatric in-patient services. Staffed with 
over 200 technical and administrative staff, the hospital treats over thirty thousand patients a 
year. Infectious diseases account for the most of  the in-patient and outpatient diagnoses, 
with malaria being the commonest cause. Tuberculosis was the third commonest cause of 
admission and the third cause of inpatient death in 2004/2005 (Arba Minch hospital statistics 
unit). 
 
 The hospital has been providing HIV counselling and testing since the early 1990’s. In 2002 
a new HIV/AIDS project was started with financial support from the Norwegian Agency for 
Development Cooperation (NORAD)/ the Norwegian Lutheran Mission (NLM).  The main 
objective of this project was to deliver antiretroviral drugs to the patients, and this was 
started in August 2003.There was some delay in providing drugs to the patients because of 
lack of national policy and guideline until recently. 124 125 The Ethiopian free ART program 
was launched in January 2005. 126  
3.2 Design of the specific studies 
The cohort study: Papers I-III 
The study population 
The specific aims 1, 2 and 3 were approached through a prospective cohort study design. A 
cohort of all HIV-infected individuals enrolled at the HIV clinic of the hospital between 
HIV antiretroviral therapy in Ethiopia 
Degu Jerene Dare 
20
January-August 2003 made up the study population for Paper I. All consecutive adult (age 
>15 years) HIV-infected patients who consented to participate in the study constituted the 
study participants. All symptomatic HIV positive adults (WHO stage II-IV), and those who 
were put on ART between August 2003 and August 2005 made up the study participants for 
Paper II.  All patients put on ART between August 2003 and January 2005, who had at least 
one follow-up visit, and followed through August 2005 constituted the study participants for 
Paper III.  
 
Data collection 
The data collection for the cohort section of the study was a part of the routine work of the 
HIV Clinic. This work was according to the National treatment guideline. 125 
 
First visit  
As part of a post-test counselling service, a counsellor referred all consenting HIV positive 
clients to a doctor after recording socio-demographic variables in a standardized form. The 
doctor recorded relevant history and physical findings and then classified the disease 
according to the WHO clinical staging . 45 We used a checklist of important symptoms and 
guidelines for staging. Following clinical staging, patients were subjected to complete blood 
cell count (CBC). Added investigations such as chest x-ray and sputum examination were 
done per clinical indication.  
 
Treatment and follow-up plans 
During the pre-ART period (before August 2003), all patients were scheduled to have 12 
weekly follow-up. Also, they were encouraged to visit the clinic any time they felt sick. On 
each subsequent visit, a doctor asked them about new symptoms since the last visit and 
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relevant physical findings including body weight were recorded. Then CBC and other 
indicated tests were repeated. Patients were treated for identified illnesses according to the 
standard in the hospital.  
 
After ARVs were made available in August 2003 (ART period), those with clinical 
indication for ART according to the National treatment guideline 125 were provided with 
adherence counselling. Once an agreement was reached to start ART, the doctor requested 
liver and renal function tests.  
 
Availability and clinical indications dictated the exact drug regimen. After recording 
information, drugs were prescribed as advised by the Drug Administration and Control 
Authority (DACA). The following drugs were approved for district hospitals at the time of 
the study: Zidovudine (ZDV), Lamivudine (3TC), Stavudine (d4T), Nevirapine (NVP), 
Efavirenz (EFV), and a fixed combination of ZDV and 3TC. 127The list of possible 
combinations included: ZDV+3TC/EFV, ZDV+3TC/NVP, d4T+3TC/EFV, and 
d4T+3TC/NVP. After starting ART, follow-up was scheduled at 4-weekly intervals to refill 
drugs. Patients were encouraged to report whenever they developed drug side effects or 
worsening of their health condition was noticed.  
 
Monitoring treatment response and drug toxicity 
Patients were asked about disease symptoms and drug side effects at each clinic visit. Body 
weight was also measured at each clinic visit. CBC and organ function tests (liver and renal) 
were done at weeks 4 and 12, 12-weekly after that and whenever clinically indicated.  
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Home visits 
Two community agents followed the patients at community level. These were secondary 
school graduates with extra training on HIV and AIDS. We assigned each of them to the 
newly recruited patients with their contact details.  They visited the patients each month at 
their home and provided home-based counselling and support during the pre-ART period 
(Paper I). During the ART period (Papers II and III), the community agents encouraged 




Time to death and time to diagnosis of tuberculosis were the main outcome measures for 
Papers I and II. Secondary outcome variables were time to WHO stage change (Paper I), loss 
to follow-up and transfer to other places. Time to death was the main outcome measure in 
Paper III. 
 
The cross-sectional design: Paper IV 
The study population 
 All adult (age>15 years) tuberculosis patients who attended the DOTS clinic of the hospital 
constituted the study population. Consenting patients who visited the clinic during January-
June 2005 were the study participants.  
 
Data collection techniques and tools 
We interviewed all consenting patients. At the end of the interview, we asked the patients if 
they accepted a pre-test counselling. Those who accepted the invitation, were counselled and 
tested. We informed the patients on the same day or within the shortest possible time. If the 
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patient refused testing, it was regarded as non-acceptability of pre-test counselling. If the 
patient did not return for the results within 2 weeks, we labelled it as non-acceptability of 
post-test counselling.  
3.3 Sample size and statistical power 
 In survival analysis, which was the main analysis technique in our study, the outcome 
variable (weeks of survival), is a continuous variable. In reality, however, what is actually 
being assessed is not time itself but the proportion of subjects who are still alive at each 
point in time. Thus, a reasonable approximation can be made by dichotomizing the outcome 
variable at the end of the anticipated follow-up period. 128 We used this principle in the 
calculation of sample size for Papers I-III. 
 
Assuming WHO disease stage as main predictor of mortality rates at the end of the study, 
our null hypothesis was there would be no difference in mortality between stage I-II and 
stage III-IV (Paper I). Similarly, in Paper III, we assumed that the WHO clinical stage, 
categorized as Stage IV versus Stage II-III, would be the main predictor of mortality in 
treated patients. The alternative hypothesis was there would be difference in mortality. From 
pilot analysis, the mortality rate was 37% (P1=0.37) in stages III-IV, and 20% (P2=0.20) in 
stages I-II at about 20 weeks of follow-up. Assuming alpha (two-sided)=0.05 and power 
90%, we determined a minimum sample size of 91 for each group both for Papers I and III. 
128  
In order to compare the mortality rate between the pre-HAART and the HAART group 
(Paper II), we assumed that 30% and 12% of patients in the pre-HAART and HAART 
cohorts, respectively, would die at the end of the follow-up. Using the same alpha and 
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power, we arrived at a minimum sample size of 91 in each cohort. 128 Assuming that about 
20% of the patients will be lost to follow-up, we adjusted for the loss by a factor of 1/ (1/1-
0.20)=1.25.  
 
Therefore, the minimum sample size for each exposure group in the cohort part of this study 
(Papers I-III) was 134 (91x1.25=134). However, we recruited more patients in stage III than 
the other stages, as the study was done under routine care conditions. As a result, we had 
unbalanced sample sizes for Papers I and III. To check if we had adequate statistical power 
to distinguish between the hypotheses, we calculated statistical power analysis using 
OpenEpi computer software. 129 The results are summarized in Table 2. 
 
Table 2. Statistical power for the cohort study (Papers I-III) 
Data input categories Paper I Paper II III 
Number of exposed 157 185 35 
Number of unexposed  50 180 117 
Risk of death among exposed (%) 28 25.4 30 
Risk of death among unexposed (%) 6 13.9 10 
Two-sided confidence interval (%) 95 95 95 
Definition of  exposure category    
Exposed Stage III-IV Pre-HAART Stage IV 
Unexposed Stage I-II HAART Stage II-III 
Risk ratio detected 4.7 1.8 3 
Power based on normal approximation 90.5 79.1 84.3 
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For the cross-sectional study (Paper IV), we planned to include all the patients who visited 
the clinic during the data collection period. We were able to recruit 190 patients. While study 
size determination can be aided by conventional formulas, such decision must also 
incorporate unquantified practical constraints such as time and finances. 130 In our case, it 
was time which limited us from including more patients. 
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3.4 Data Management and statistical analysis 
Statistical methods 
We used SPSS (SPSS Inc, Chicago, USA) software for data processing and analysis. Data 
analysis was performed when data collection was completed for each study. Our main 
method of analysis for the cohort part of the study was survival analyses. We used the 
Kaplan-Meier (KM) method for event-free survival, and the Cox Regression (CR) method to 
evaluate the relative effect of selected variables. The Log-rank test (for the KM) and the 
hazard ratios (for the CR) were used to test for statistical significance. For the cross-sectional 
part (Paper IV), we used the Logistic regression method to assess factors affecting 
acceptability. All statistical tests were considered significant if the two-sided P-value <0.05. 
Table 4 summarizes the main statistical methods. 
 
Data safety and quality assurance 
Patient records were kept in the clinic in hard-cover file holders in a lockable shelf. Only 
authorized personnel had the keys to the rooms and to the shelves. Access to databases was 
restricted by passwords known to the principal investigator and to the data clerk. Back-ups 
were taken on a daily basis and kept in the investigator’s home. Completed questionnaires 
(Paper IV) were archived in the investigator’s office in a lockable shelf. 
 
In order to assure consistency of information gathered in the clinic, checklists of important 
symptoms and signs were posted in front of the doctor’s desk and on the walls in the offices. 
The doctors, nurses, and laboratory technicians working with the HIV unit completed the 
necessary national courses. The doctors also attended a one-month course in comprehensive 
HIV care at Makerere University in Uganda. 
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Table 4. Summary of study design, population, tools and main statistical methods 





I 207 untreated HIV 
patients 





II 185 untreated patients 
180 treated patients 
Prospective cohort Clinical records 
Home visits 
Kaplan Meier  
Cox 
regression 
III 162 treated patients 
 
Prospective cohort Clinical records 
Home visits 




IV 190 tuberculosis 
patients 
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Refresher courses were arranged when areas of weakness were detected. The principal 
investigator made unannounced visits to homes of randomly selected patients every 2-3 
months. Field reports were checked for consistency on a monthly basis. 
 
3.5 Ethical Considerations 
Ethical approval was obtained form the Regional Committee for Medical Research Ethics in 
Bergen, Norway, and from the National Ethics Review Committee in Ethiopia. All patients 
gave informed written consent for HIV testing and for participating in the study. Treatment 
of patients was according to the National treatment guideline. Prompt medical treatment was 
given to all patients irrespective of their consent. All patient records were kept in a 
confidential way as described above.  
HIV antiretroviral therapy in Ethiopia 
Degu Jerene Dare 
29
4 SYNOPSES OF THE PAPERS 
 
Paper I: Disease progression among untreated HIV infected patients in south Ethiopia: 
implications for patient care 
Understanding the natural course of HIV disease progression is important for clinical 
decision making, for modelling the epidemic, and for planning interventions at programme 
level. In resource-limited settings, such information is poorly documented. In this study, we 
described the short-term disease progression pattern among Ethiopian patients under routine 
clinical care conditions. 
 
Recruitment into the cohort started in January 2003, as a part of the preparation to start ART. 
After initial assessment and WHO staging patients were reassessed every 12 weeks. We 
documented new stage-defining events and measured CBC at each visit. Patients received 
the standard care in the hospital. Death, diagnosis of tuberculosis and change in disease stage 
were the outcome measures. Two community agents reported patient status every month. We 
used the Kaplan-Meier and Cox-regression methods to assess predictors of disease 
progression. 
 
We followed 207 patients for a median duration of 19 weeks.132 (64%) patients were in 
WHO stage III. The Mortality rate was 46 per 100 person-years of observation (PYO). 
Mortality increased with advancing disease stage. Diarrhoea, oral thrush and low total 
lymphocyte count were significant markers of mortality. Tuberculosis incidence rate was 9.9 
per 100 PYO. Easy fatigability and fever were strongly associated with tuberculosis 
(HR=15.6, 95%CI=2.8-87.5 for weakness; HR=9.2, 95%CI=1.9-44.5). 
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Oral thrush, diarrhoea and total lymphocyte count predicted mortality, and easy fatigability 
and fever predicted tuberculosis. In settings with scarce resources, patients with oral thrush, 
diarrhoea or low total lymphocyte count should be prioritized for treatment. Patients with 
history of prolonged fever and easy fatigability are at higher risk of developing tuberculosis 
and thus require close attention.  
 
Paper II: Antiretroviral therapy at a district hospital in Ethiopia prevents death and 
tuberculosis in a cohort of HIV patients 
In resource-poor settings, the effectiveness of HAART has not been fully studied. Our aim 
was to assess the effect of HAART on patient mortality and tuberculosis incidence rate 
under routine clinical care conditions in a resource-limited setting in south Ethiopia. Starting 
in January 2003, we followed all consecutive adult HIV infected patients who visited the 
HIV clinic. Since August 2003, we treated patients with HAART. Only basic laboratory 
services were available.  
 
We followed 185 patients in the pre-HAART cohort and 180 patients in the HAART cohort. 
The mortality rate was 15.4 per 100 person-years of observation (PYO) in the HAART 
group and tuberculosis incidence rate was 3.7 per 100 PYO. In the pre-HAART group, the 
mortality rate was 58.1 per 100 PYO and the tuberculosis incidence rate was 11.1 per 100 
PYO. HAART resulted in a 65% decline in mortality (adjusted hazard ratio [95%CI] =0.35 
[0.19-0.63]; P<0.001). Tuberculosis incidence rate was lower in the HAART group (adjusted 
hazard ratio [95%CI] =0.11 [0.03-0.48]; P<0.01). Most of the deaths occurred during the 
first three months of treatment. 
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HAART improved survival and decreased tuberculosis incidence to a level similar to that 
achieved in the developed countries during the early years of HAART. However, both the 
mortality and the tuberculosis incidence rate were higher in this resource-limited setting. 
Attention should be paid to the early weeks of treatment when mortality is high. The high 
tuberculosis incidence rate, when coupled with the improved survival, may lead to increased 
tuberculosis transmission at the community level. This highlights the need for strengthening 
tuberculosis prevention efforts with the scale-up of treatment programmes. 
 
Paper III: Predictors of early death in a cohort of Ethiopian patients treated with 
HAART 
Although the survival of HIV infected patients has improved following the introduction of 
HAART, patients in resource-poor countries have higher mortality rates especially during 
the first weeks of treatment. In this study, we examined factors predicting mortality in 
Ethiopian patients treated with HAART.  
 
We treated patients using the WHO clinical stage and the TLC as criteria for beginning 
treatment. We measured body weight and CBC at baseline, 4 weeks later, then repeated 
weight every month and CBC every 12 weeks. Time to death was the main outcome 
variable. We used the Kaplan Meier and Cox regression survival analyses to identify 
prognostic markers. We also calculated mortality rates for the different phases of the follow-
up.  
 
Out of 162 recruited, 152 treatment-naïve patients contributed 144 person-years of 
observation (PYO).  86 (57%) of them were men and their median age was 32 years.  The 
overall mortality rate was 16.7 per 100 PYO (24 deaths/144.1 PYO). The highest death rate 
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occurred in the first month of treatment. Compared to the first month, mortality declined by 
9-fold after the 18th week of follow-up. Being in WHO clinical stage IV and having 
TLC<=750/mcL were independent predictors of death. BMI <=18.5 kg/m2 at baseline was 
associated with death in univariate analysis. Weight loss was seen in about a third of patients 
who survived up to the fourth week, and it was associated with increased death. Decline in 
TLC, HGB and BMI was associated with death in univariate analysis only. 
 
The high early mortality associated with advanced disease stage highlights the need for 
identifying and treating patients early. Underlying causes for the early death should be 
investigated.  
 
Paper IV: Acceptability of HIV counselling and testing among tuberculosis patients in 
south Ethiopia 
To benefit from the available care and treatment options, patients need to know their HIV 
status. Many  tuberculosis patients are also HIV infected and they represent patients with 
advanced disease. Our aim was to assess the acceptability of HIV testing among tuberculosis 
patients under routine care conditions in south Ethiopia. 
 
We asked adult tuberculosis patients who were treated at Arba Minch Hospital between 
January and August 2005 if they were willing to be counselled and tested. Those who 
showed willingness were counselled and tested, and told about their results. Using the 
logistic regression method, we assessed factors associated with willingness and 
acceptability.  
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Among 190 ptients (52% men), 49(26%) were previously tested including 29 (59%) HIV 
positive. Of 161 remaining patients, 118 (73%) were willing to be tested and 58% (68/118) 
of those willing accepted the test, making the overall acceptability rate 35% (56/161). 
Fourteen (20.6%) were HIV positive and women were more likely to be HIV infected. 
Unemployment and self-perceived high risk of HIV infection were associated with initial 
willingness. However, only unemployment was associated with accepting the test. 
 
The low acceptability of HIV counselling and testing among tuberculosis patients poses a 
challenge to the scale-up of TB/HIV collaborative efforts. Added methods such as routine 
asking of the patient’s previous history of HIV testing should be encouraged.  
 
Additional results 
Between December 2005 and March 2006, baseline CD4 count was available for 105 
treatment naïve patients (44 men and 61 women). Their median (range) age was 33 (15-60) 
years. Baseline WHO disease stage was available for 82 patients (77%) including 59/82 
(72%) in stage III, 13/82 (16%) in stage IV, 7/82 (8%) in stage II, and 3/82 (4%) in stage I. 
Their median CD4 and TLC values were 210 cells/mcL (95% range; 7, 1003) and 1500 
cells/mcL (95% range; 332, 3735), respectively. The CD4 count was positively correlated 
with TLC (r=.518, P<.001, n=98), BMI (r=.311, P=.002, n=98) and WT (r=.231, P=.022, 
n=98).  
 
TLC<=1200/ml predicted CD4 <=200/ml with sensitivity of 59%, specificity of 79%, PPV 
of 52% and NPV of 73%. Addition of BMI<=18.5 kg/m2 increased the sensitivity to 61% 
and the PPV to 70%, but the NPV decreased to 71%.  TLC<=1200/ml predicted CD4<=100 
HIV antiretroviral therapy in Ethiopia 
Degu Jerene Dare 
34
with sensitivity 73%, specificity 77%, PPV 56%, and NPV 88%. Addition of HGB and/or 
BMI did not improve the models.  
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5 DISCUSSION 
5.1 Discussion of methods 
Study design 
Our main study design was a cohort study. Cohort studies track people forward in time from 
exposure to one or more outcomes. Data collection may occur in the same direction 
(prospective cohort study), in the opposite direction (retrospective cohort study), or in both 
directions (ambidirectional).  131 In this study (Papers I-III), we collected prospective data 
under routine clinical care conditions. 
 
Cohort studies have several advantages. They are useful to ascertain both incidence and 
natural history of a disease. They are also important in investigation of multiple outcomes 
that might occur after a single exposure. The cohort study design is suitable for studying rare 
exposures, and it reduces the risk of survivor bias. Cohort studies also allow calculation of 
incidence rates, relative risks, and other outcome measures such as survival analyses. 131 
 
Cohort studies have disadvantages too. 131 Selection bias is built into cohort studies. Loss to 
follow-up can be a problem, and cohort studies are not suitable for studying rare diseases. 
Before-after cohort studies have important limitations. Here, an investigator takes a 
measurement, exposes participants to an intervention, repeats the measurements, then 
compares them. First, regression to the mean is often ignored. If admission to the cohort 
includes extreme measurements, such as high laboratory values, then lower mean values will 
arise at follow-up, irrespective of treatment. Second, secular trends, such as seasonal 
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changes in disease frequency, can affect results. Third, washout periods are often needed to 
avoid carryover effect of drugs given during the initial observation period. 131 In our study, 
loss to follow-up was minimal. Because the follow-up period crossed both rainy and dry 
seasons, the secular trends are unlikely to affect the outcome. Since we compared no 
treatment with treatment situation, there was no need for washout period.   
 
In principle, a cohort study could be used to estimate average risks, rates, or occurrence 
times. This requires that the whole cohort remain at risk and under observation for the entire 
follow-up period.  130 In practice, patients may be lost, transferred, or die of competing 
causes. When losses or competing risks do occur, one may still estimate the incidence rate 
using survival methods. 130 In our cohort, loss to follow-up was minimal and we used 
survival methods to estimate predictors and rates of death and disease.  
 
An individual can contribute person-time to one or more exposure groups in a study, because 
each unit of person-time contributed to follow-up by a person possesses its own 
classification with respect to exposure. 130 Thus an individual whose exposure changes with 
time may contribute follow-up time to several exposures. This explains the design in Paper 
II, where 85 patients contributed person-time to both the pre-HAART and the HAART 
cohorts. These are patients whose exposure experience (pre-HAART versus HAART) 
changed with time. 
 
Validity 
The validity of a study is classified into two: internal validity and external validity (or 
generalizability).  
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Internal validity is the ability of a study to measure what it sets out to measure. It shows the 
accuracy of inferences that can be drawn from study participants. Internal validity is a pre-
requisite for external validity. In clinical research, extrapolation of invalid results to the 
broader population is worthless and potentially dangerous. 132 
 
Internal validity implies accurate measurement of effects apart from random errors. 
However, all observational studies have built-in bias, and bias undermines the internal 
validity of a study. The three major types of bias include: selection bias, information bias, 
and confounding. 130 132  
 
Selection bias stems from lack of comparability of groups studied. It results from procedures 
used to select subjects and from factors that influence study participation. The common 
element of such biases is that the relation between exposure and disease is different for those 
who participate and those who should be theoretically eligible for study, including those who 
do not participate. The result is that associations observed in the study represent a mix of 
factors affecting participation, as well as factors determining disease.  130 In our cohort 
(Papers I-III), we included all adult HIV infected patients who willingly came to our clinic 
for medical care following post-test counselling. Therefore, selection bias is unlikely to 
occur in this study.  
 
Information bias, also called measurement bias, results from incorrect determination of 
exposure or outcome, or both. In a cohort study, information about outcomes must be 
obtained the same way for those exposed and unexposed. The main outcome measures in our 
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study (Papers I-III) were death, diagnosis of tuberculosis, and change in specific laboratory 
values. Lack of information about specific causes of death might have resulted in incorrect 
determination of outcome. Since diagnosis of extrapulmonary and smear negative pulmonary 
tuberculosis was dependent on the clinical judgement of a doctor, difference in clinical 
experience might have resulted in measurement bias. The same is true for the WHO clinical 
staging. Failure to recognize a stage-defining sign or symptom may result in variations in 
disease stage.  Although the haematological parameters were determined by automatic 
machines, differences in the handling of the samples might have resulted in measurement 
bias. 
  
Confounding is a mixing or blurring of effects. A researcher attempts to relate an exposure 
to an outcome, but actually measures the effect of a third variable, termed a confounding 
variable. A confounding variable is associated with the exposure and it affects the outcome, 
but it is not an intermediate link in the chain of causation between exposure and outcome. 130 
 
Confounding is correctable provided potential confounders are anticipated. It can be avoided 
by restriction, matching, stratification, and by multivariate techniques. In our study, we used 
various regression models to control for the relative effect of potential confounders.  In 
Paper I, for example, we included oral thrush, TLC, HGB, WHO clinical stage, Diarrhoea, 
and BMI in a multivariate Cox regression analysis to see if these variables were independent 
predictors of death. Only TLC<=1200/ml and oral thrush were found to be independent 
markers of death.  
 
In Paper II, we examined if the observed difference in mortality between pre-HAART and 
HAART cohorts was the effect of treatment. As shown in Table 3 in Paper II, treatment with 
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HAART was the strongest predictor of improved survival. We further checked for 
multicolinearity between HAART and TLC, and HAART and BMI. The interaction term 
was not significant (P>0.1 in both), suggesting that HAART prevents death irrespective of 
the patient’s TLC and BMI values. 
 
In Paper III, we made detailed analysis of factors predicting mortality for the different 
phases of the follow-up. Here, we found that that the TLC<=750/ml and WHO clinical stage 
were independent predictors of mortality. We demonstrated that the WHO clinical stage was 
a better predictor of deaths that occur in the first month of the follow-up, while the 
TLC<=750 was a better predictor of overall mortality.  
 
External validity 
External validity refers to the validity of the inferences as they apply to people outside that 
population. In other words, external validity gauges the applicability of study results under 
routine care conditions.  130 132 Applicability of study results outside the study setting 
depends on the feasibility, coverage, and acceptability of the interventions. 133 Feasibility of 
health interventions depends on capacity of care providers, has some cost dimensions, and 
may require the existence of other health services. To be applicable, an intervention must 
achieve adequate coverage which in turn depends on the overall comprehensiveness of 
health coverage. Acceptability determines the recipients’ level of adherence to treatment and 
follow-up plans, and it may vary between populations depending on cultural norms and cost 
of the interventions. 133  
 
Although our study was observational, results of observational studies may approximate 
those of randomized trials if conducted properly. 134 Therefore, factors that affect results of 
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randomized trials are likely to affect the generalisability of our findings. For example, the 
presence of community agents as additional service providers might have introduced some 
differences in the outcome of treatment. The doctors had also received advanced trainings on 
clinical management of HIV which might have created a better capacity of care providers 
than in most other district hospitals in Ethiopia.  
 
The findings of this study can be generalized to adult HIV-infected treatment-naïve patients 
in public health settings in Ethiopia, or even in other resource-limited settings in Sub-
Saharan Africa for a number of reasons.  First, we did the study under routine care 
conditions in a typical district hospital in Sub-Saharan Africa. Second, no strict exclusion 
criteria were applied except in the analysis of the laboratory data in Paper III where 10 
patients with previous exposure to ARVs were excluded. Third, loss to follow-up was 
minimal. Moreover, our results agree with findings from other studies in similar settings. 
The decline in mortality rate and tuberculosis incidence rates in patients treated with 
HAART is consistent with reports from other African countries. 135 136 The increased early 
mortality in treated patients concurs well with a large multicentre study and consistent with 
reports from Senegal and South Africa. 137-139 
5.2 Discussion of main results 
Disease progression among untreated patients 
Natural history studies of untreated HIV disease are useful for clinicians, public health 
experts and policy makers. Such information is important for developing treatment 
guidelines, for modelling the epidemic, and for prioritizing and allocating resources. Since 
effective treatment for HIV infection has existed since early in the epidemic, the natural 
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course of HIV disease progression has been poorly documented. Most of the studies were 
conducted in developed countries. We have limited information from the resource-limited 
settings. Some of the earlier studies reported faster disease progression in African patients 
than in patients from the developed world. 140 141 However, recent evidence suggests that no 
difference exist. 41 The apparently faster disease rate among Africans could be due to late 
presentation to the health service, higher rates of co morbid clinical conditions, and lack of 
prophylaxis for opportunistic infections. The difference in disease classification could be 
additional factor.  
 
In Paper I, we presented the pattern of short-term disease progression among untreated 
patients. The short follow-up and lack of information about the date of HIV infection limited 
us from describing the full picture of the natural history of HIV infection. However, we 
identified short-term prognostic markers that are of practical importance in resource-limited 
settings.   
 
The WHO staging system, which has clinical and laboratory components, has rarely been 
used in routine clinical practice in Ethiopia. It has been in use in selected research projects in 
the country including a validation study which described the clinical usefulness of the 
clinical axis of the WHO staging system. 142 In their cross-sectional validation study, which 
included both clinical cohorts and participants from a cohort of factory workers, Kassa et al 
demonstrated that the WHO clinical staging correlated positively with the CD4 count, and 
negatively with the plasma viral load. Moreover, they found that the hospital cohorts were 
different from the factory cohorts, the former group presenting with advanced disease, as is 
in our study (Paper I). Our study further showed the prognostic value of the WHO clinical 
staging under routine clinical care conditions in a prospective cohort of patients.  
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 Moreover, our findings suggest that some stage-defining events such as the oral thrush and 
diarrhoea can be useful in further stratification of patients for clinical decision-making. 
Some modifications in the WHO staging system were suggested by some authors. 143 144 
Lifson et al, for example, suggested addition of oral thrush, pulmonary tuberculosis and 
chronic oral or genital ulcer, and substitution of BMI for weight loss as Stage IV-defining 
diseases. 144 Their suggestion was based on findings from a cohort of Rwandan women who 
were followed for four years. In their study, the WHO stage III and IV were 
indistinguishable after 12 months of follow-up, but provided clear distinction during the first 
year. Since ART is now widely available, pre-ART follow-up is likely to be much shorter 
than 1 year in symptomatic patients, perhaps even shorter than the 19 weeks’ of follow-up in 
our cohort.  In the most recent version of the WHO staging system, oral thrush is categorized 
under stage III. 47 
 
The main purpose of staging in clinical practice is to time the initiation, changing, or 
stopping of chemoprophylaxis and antiretroviral therapy. In resource-limited settings, this is 
an important issue. Mekonnen et al described a set of simple markers (TLC, HGB, and BMI) 
as important prognostic markers that can be used in timing of treatment beginning. 145 They 
did this study among a cohort of HIV infected factory workers who were likely to be in less 
advanced clinical stage than our patients (Paper I). 142 We also used slightly different cut-off 
points for haemoglobin and TLC. In both studies, however, the direction of association 
between these markers and mortality was the same, i.e., low TLC, anaemia, and low BMI 
predicted death, suggesting their potential utility in deciding when to start or stop treatment 
and prophylaxis.  
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Like the mortality, tuberculosis incidence rate was high at 9.9 per 100 PYO;   twice as high 
as in HIV positive factory workers in Ethiopia. 145 In Cape Town, tuberculosis incidence rate 
was 10.4 per 100 PYO in HIV positive adults, and being in WHO stage III and IV was a 
strong risk factor.  146 The non-significant association between disease stage and tuberculosis 
in our study could partly be because of the smaller sample size. The striking finding in our 
study was the significant association between easy fatigability and fever, and tuberculosis. 
Undiagnosed tuberculosis could be a possible explanation, suggesting the need for improved 
diagnostics.  The high tuberculosis incidence rate also implies the need for some 
prophylactic measures. 
 
Effect of HAART on mortality and tuberculosis incidence rate 
Most early publications on the effectiveness of HAART originated from industrialized 
countries and the comparisons were population based.147-151 Moreover, some were based on 
selected group of patients, making the generalizability to other group of patients difficult. 
The reduction in mortality also varied remarkably, ranging from 20.7% in Brazil to 79% in 
Australia .150 151 
 
Several factors may result in variations in population based reductions in AIDS-related 
mortality and morbidity. These include, but perhaps not limited to, variation in study design, 
recruitment criteria, years analyzed, extent of HAART use and adjunctive medical 
treatments. Despite the difference in the magnitude of change in mortality and morbidity, the 
direction of change was consistent in all these studies, i.e., reduction in death or illness. 
 
Some studies have measured the direct effect of HAART. In patients with advanced HIV 
disease, for example, Pallela et al reported a 4.5 times higher risk of death in untreated 
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patients compared to patients who received a PI-containing antiretroviral therapy. 152 In 
Taiwan, use of HAART was associated with a 75% reduction in mortality in patients with a 
CD4 count less than 100/mcL. 153 In a more recent study from China, a 79% reduction in 
mortality was achieved for patients with CD4 count less than 200/mcL. 154  
 
A 65% reduction in mortality associated with HAART in our patients (Paper II) is consistent 
with findings from the developed world during the early years of treatment. A protease 
inhibitor-containing HAART reduced mortality by 64% in an Italian cohort .155 156 Similarly, 
a multicentre HAART trial reported a 62% decrease in mortality among patients with 
advanced HIV. 156 A study from Kenya reported a very low mortality rate (5.4%), but 24.5% 
of their patients were lost to follow-up. 157 We had accurate information and little loss to 
follow-up because of the community agents and  the prospective nature of the data. 
Therefore, ours is likely to represent the actual situation at a primary health care setting in 
Africa. 
 
Most of the deaths in our patients occurred during the early weeks of treatment (Paper II). 
When compared with patients from high-income countries, patients from low-income 
countries were about four times more likely to die during the first months while on HAART, 
and the mortality rate was 147 per 1000 PYO. 139 The mortality rate of 15.4 per 100 PYO in 
HAART treated patients correlates well with this finding. Increased mortality in the early 
weeks of mortality appears to be associated with the advanced disease stage at presentation 
in resource-poor settings. Tuberculosis, drug side effects, and the immune reconstitution 
syndrome could be contributing causes. 158 Strategies aimed at early recognition and 
management of tuberculosis, drug side effects and immune reconstitution syndromes are 
likely to improve the high early mortality.  
HIV antiretroviral therapy in Ethiopia 
Degu Jerene Dare 
45
 
In South Africa, the tuberculosis incidence rates in the HAART and in the pre-HAART 
cohort were 2.4 and 9.7 per 100 PYO, respectively. Tuberculosis was more likely to occur 
among patients with advanced HIV disease suggesting the need for early initiation of 
antiretroviral therapy. 136 In our study (Paper II), tuberculosis incidence rates were 3.7 and 
11.1 per 100 PYO in the treated and untreated patients, respectively.  Tuberculosis incidence 
rate declined from 3.5 per 100 PYO in the first year to 1.01 per 100 PYO in the fifth year. 135 
Higher risk of relapse was reported in patients with previous history of tuberculosis in a 
western African cohort. 159 Though this has not been confirmed in other studies, the authors 
suggested the use of secondary prophylaxis in patients with previous history of tuberculosis.  
The high early mortality possibly associated with tuberculosis and the high incidence rate of 
tuberculosis in patients treated with HAART highlights the need for coordinating 
tuberculosis control programs and HIV treatment efforts. 160-162  
 
Predictors of early mortality in treated patients 
Compared to patients in high-income countries, patients in low-income countries have 
higher mortality rates especially during the first months of treatment. 137-139 In Paper III, we 
made a more detailed examination of factors associated with early death in Ethiopian 
patients. 
 
Being in WHO clinical stage IV and having the TLC<=750/mcL at the beginning of 
treatment were the two most important predictors of death in this cohort. This highlights the 
need for starting treatment before patients progress to such advanced stages. Patients need to 
be identified early through improved counselling and testing strategies.  
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The TLC<=1200/mcL is often recommended as the cut-off point for beginning treatment. 
However, we found a much lower cut-off point, TLC<=750/mcL, as significant predictor of 
death.  Similarly, HGB<=10g/dl and BMI<=18.5 kg/m2 were not significantly associated 
with increased death. This could be because of the small number of patients and events with 
TLC, HGB, and BMI above the stated cut-off points.  
 
In some Asian and African populations including Ethiopians, the normal CD4 range is low 
and therefore the same TLC may not be used as a surrogate marker for CD4 count. 163-165 In 
Chinese patients, the TLC<=1200/mcL predicted the CD4<=100/mcL with better sensitivity 
and specificity than CD4 <=200/mcL. 166  
 
Although the availability of ARVs has improved during the last few years, lack of suitable 
monitoring approaches has continued to be a barrier to access. 81 The majority of patients 
residing in rural villages and smaller towns could not access these services. Even if the 
equipment is made available, lack of trained personnel and poor infrastructure such as 
frequent power failures represent major obstacles. 85 
 
Several approaches can be proposed to overcome this challenge. Inventing simplified, low-
cost technology is one possibility. Some have suggested the use of dried whole blood spots 
to measure CD4 counts as alternatives to the standard flow cytometry technique which 
requires fresh blood samples. 167 A manual bead assay technique was also shown to correlate 
well with the flow cytometry technique. 168 Such initiatives should be viewed as long-term 
strategies, but they are still far from reach in the settings where they are most needed.  
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The more possible alternative seems the use of simple clinical and laboratory markers such 
as the TLC, HGB, body weight and BMI. Several authors both from low-income and high-
income countries have demonstrated that these simple markers correlate fairly well with 
CD4 count, and thus could be used to monitor immunological response to ART. 166 169-172 
However, most of these studies were done among untreated patients and utilized cross-
sectional data. Future prospective studies should examine the utility of these simple markers 
in treated patients. 
  
Weight loss continues to be a significant problem even among patients treated with HAART. 
173 The aetiology of weight loss is complex and multifactorial. 174 The underlying reasons 
could be infectious diseases (example, tuberculosis), nutritional disorders, immune 
reconstitution inflammatory syndrome (IRIS), or drug side-effects. There is little information 
from resource-limited settings regarding weight loss in treated patients. In our study, weight 
loss was present in a third of patients who survived up to the fourth week of treatment. 
Future prospective studies should, therefore, define the magnitude, causes and consequences 
of weight loss among resource-poor patient populations. Such observational studies will 
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HIV testing and counselling among tuberculosis patients 
Historically, tuberculosis and HIV/AIDS prevention and treatment have been approached 
differently. This made the TB/HIV collaborative efforts difficult. 175 Tuberculosis control 
programmes have used a public-health approach of case finding, name-based case 
notification, and at times contact tracing. The focus was on control of tuberculosis 
transmission and prevention of drug resistance. Little attention was paid to patient-centred 
goals such as reduction in death. 176 On the other hand, HIV/AIDS programmes have 
focused on individual approach to HIV testing which is private, confidential, and voluntary. 
177 
 
In an effort to narrow the gap between the control programs for tuberculosis and HIV, the 
WHO now encourages closer collaboration between the two programs. 178 Routine 
counselling and testing of tuberculosis is a component of such an effort. With the improved 
access to antiretroviral therapy, there is a greater need to test more people for HIV. This 
cannot be achieved with the traditional VCT alone and alternative testing strategies are 
needed. 177 179 
 
The low acceptability rate of HIV testing and counselling in our study (Paper IV) shows part 
of the challenge we may be facing in counselling and testing as many people as who need 
care and treatment. Only a third of patients who needed counselling and testing utilized the 
service. Moreover, unemployed people who are likely to need financial support because of 
their HIV status were more likely to be tested. A delay in providing the service could occur 
at any stage of the counselling and testing process, turning more people away from getting 
the service as evidenced by much lower acceptability rate of testing among patients who had 
some kind of employment.  Short counselling session followed by rapid HIV testing at the 
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DOTS clinic itself could have improved the acceptability rate. Whether such approaches 
would work requires further evaluation in the appropriate setting. 
 
De Cock et al emphasized the importance of introducing routine diagnostic HIV testing in 
Africa: “If the benefits of antiretroviral treatment and prevention of opportunistic infection 
are to reach the people who need them, routine diagnostic testing will have to become 
standard practice in medical care. Routine HIV testing should initially be concentrated in 
general medical and tuberculosis patients, but in the long term, testing and provision of 
follow-up information should become a routine component of all health care interactions.” 
177 Current evidence, however, shows that only about half of in-patients with HIV related 
illnesses are counselled and tested. 180The situation could be worse in Ethiopia.  
 
HIV is a life-long and potentially fatal condition for which there is no cure at the moment. 
However, the advent of the HAART changed the way people used to view HIV infection. 
HIV is now viewed as a chronic manageable condition like any other chronic disease such as 
diabetes. At the same time HIV is an infectious disease which is mainly transmitted through 
sexual route. It is an accepted practice that any medical information is confidential. But HIV 
is probably the only infectious disease which required counselling before and after testing. 
We are not arguing that HIV counselling should be abandoned. Our point is that it should be 
adapted to the changing environment of the disease itself.   
 
In conclusion, the low acceptability of HIV counselling and testing among tuberculosis 
patients shows the need for alternative counselling and testing approaches. The current HIV 
counselling and testing strategies should be adapted to the changing environment of the 
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disease itself. More patients can be identified by routine asking of their previous history of 
testing.  
5.3 Policy implications 
Many patients need antiretroviral treatment in Ethiopia. This study evaluates the 
antiretroviral therapy programme that started at Arba Minch Hospital in 2003. We show that 
it is possible to achieve good treatment results within the existing health institutions. The 
treatment reduced deaths among AIDS patients by 65%. Over 90% of the patients followed 
the treatment. Few patients experienced serious side effects of the antiretroviral drugs.  
 
Unfortunately, many patients presented themselves with advanced disease. We encourage 
telling the public so patients may start treatment earlier. This thesis provides information that 
is important in carrying out antiretroviral therapy in Ethiopia. 
 
Many health centres and district hospitals in Ethiopia do not have the capacity to do CD4 
tests. Patients should not be denied treatment because of lack of such laboratory facilities. 
We identified simple clinical and laboratory markers that can be used in the follow-up of 
patients in settings with limited laboratory setup. 
 
The main challenge is whether this way of providing ART at district hospitals in Ethiopia is 
sustainable.  The Ethiopian Health Policy focuses on thorough and integrated primary health 
care with emphasis on community based services. 181 In 2004, the Government of Ethiopia 
introduced the Health Service Extension Programme which intends to bring the health 
service close to people. According to the package, both health centres and district hospitals 
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should provide HIV care and treatment, including ART. 182 It is thus encouraging to note the 
Integrated Management of Adolescent and Adult Illness (IMAI) developed by the WHO, 
provides practical guidance on decentralised, integrated delivery of HIV care. 183  Ethiopia is 
now training many health workers on the use of the IMAI guideline. Through this approach, 
nurses and clinical officers shall provide ART to patients. Lay workers and patients will 
further have a greater role in care delivery.   
 
 
The successful implementation of our project was a result of both local and international 
collaboration. The community agents were helpful not only for securing complete data for 
the investigation, but also for the day-to-day follow-up of patient care. They acted as a 
liaison between the community and the hospital. Patient groups, such as Tesfa Goh in Arba 
Minch, also played an important role in the care delivery. We advise the Ministry of Health 
to strengthen patient organisations and community workers in the ART delivery.  
 
We found many new tuberculosis cases among patients receiving ART. Also, patients with 
tuberculosis often refused to be HIV tested. Therefore, tuberculosis control should be linked 
to HIV treatment and care. Patients with tuberculosis need to be told about ART, and HIV 
counselling and testing strategies need to be improved.  
 
We were able to conduct this research in a remote part of the country. Such research should 
be viewed as an opportunity for strengthening research capacity at the newly established 
universities in South Ethiopia. The sustainability of such efforts needs both enabling policy 
environment and resources.  
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6 CONCLUSIONS AND RECOMMENDATIONS 
Conclusions 
1. We found high mortality and high tuberculosis incidence rates among untreated HIV 
infected patients in south Ethiopia. Simple clinical and laboratory markers predicted 
both mortality and tuberculosis occurrence in this cohort. 
2. HAART improved survival and decreased tuberculosis incidence to a level similar to 
that achieved in the developed countries during the early years of HAART. Most of 
the deaths occurred during the early weeks of treatment.  
3. The baseline WHO clinical stage, change in body weight and change in total 
lymphocyte count predicted mortality in treated patients in a complementary way and 
therefore can be used in the follow-up of patients in resource-limited settings. 
4. The acceptability of HIV counselling and testing was low among tuberculosis 
patients in Arba Minch. This poses an important challenge to the scale-up of TB/HIV 





For clinical practice: 
1. In settings with limited capacity to do CD4 tests, patients with advanced HIV 
infection, particularly those with oral thrush, diarrhoea and low total lymphocyte 
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count should be treated promptly. Patients with baseline history of prolonged fever 
and easy fatigability should be followed more closely for tuberculosis. 
2. In order to prevent the many deaths that occur during the early weeks of 
antiretroviral therapy, health workers should plan for more frequent contact with 
patients during the early phase of treatment. Patients should also be informed about 
the need for early diagnosis of HIV infection and associated illnesses. 
3. Documenting the WHO stage and body weight should be viewed as important 
component of the routine clinical care for patients on antiretroviral therapy. 
4. Health workers in the TB/HIV treatment units should be prepared to practice HIV 
counselling and testing as routine part of their work. 
 
For research: 
1. Since tuberculosis is a common problem even among patients receiving HAART, 
the feasibility, acceptability and effectiveness of INH preventive therapy should be 
evaluated in patients treated with HAART.  
2. Factors that lead to increased mortality during the early weeks of treatment should 
be identified and interventions should be planned for. Particular attention should be 
paid to infectious and potentially treatable or preventable causes such as 
tuberculosis, drug toxicities and nutritional disorders. 
3. The mechanism and magnitude of weight loss among patients treated with HAART 
needs further research. 
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4. Whether our model of care would work in other settings (example, health centres) 
under the leadership of primary health care workers needs further research.  
 
For policy: 
1. Simple clinical and laboratory markers should be incorporated in the revision of   
antiretroviral treatment guidelines.  
2. Our model of integrating research into the routines of the primary health care settings 
should be encouraged. The sustainability of such models requires strengthening the 
existing links and developing new partnerships between the academia and disease 
control/treatment efforts.  
3. The Ethiopian HIV counselling and testing policy should be adapted to the changing 
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